Phenotypes Associated with This Genotype

Genotype
MGI:4358554

• Allelic Composition: Kit^tm3.1Bsm/Kit^tm3.1Bsm
• Genetic Background: B6.129S1-Kit^tm3.1Bsm

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

mortality/aging

increased susceptibility to xenobiotic induced morbidity/mortality ( J:146561 )

• mice treated with a myelosuppressive dose of 5-fluorouracil (5-FU) die between 6 and 16 days post-treatment unlike similarly treated wild-type mice

hematopoietic system

abnormal stress erythropoiesis ( J:146561 )

• following phenylhydrazine (PHZ)- or 5-fluorouracil (5-FU)-induced anemia, stress-induced erythropoiesis is defective compared to in wild-type mice

abnormal proerythroblast morphology ( J:146561 )

• the ratio of Kit+ to Kit- proerythroblasts is decreased while the frequencies of Kit- erythroblasts is increased compared to in wild-type mice

• proerythroblast exhibit decreased proliferation and survival capacities compared to in wild-type mice

• following treatment with phenylhydrazine (PHZ), mice exhibit decreased frequency of bone marrow erythroid cells compared with similarly treated wild-type mice

increased erythroblast number ( J:146561 )

• mice exhibit a 2-fold increase in Kit^negCD71^high erythroblasts compared with wild-type mice

decreased erythrocyte cell number ( J:146561 )

• following treatment with EPO, red cell levels at 6 and 9 days are deficient compared to in similarly treated wild-type mice

decreased hematocrit ( J:146561 )

• following treatment with a myelosuppressive dose of 5-fluorouracil (5-FU), hematocrit levels fall markedly prior to death between 6 and 16 days post-treatment unlike in similarly treated wild-type mice

• following treatment with a standard dose of 5-FU mice exhibit decreased hematocrit levels compared with similarly treated wild-type mice

• following treatment with phenylhydrazine (PHZ), mice exhibit deficient hematocrits compared with similarly treated wild-type mice

increased mean corpuscular volume ( J:146561 )

• during recovery from a standard dose of 5-fluorouracil (5-FU) compared to in similarly treated wild-type mice

spleen hypoplasia ( J:146561 )

• following treatment with phenylhydrazine (PHZ)

homeostasis/metabolism

abnormal response/metabolism to endogenous compounds ( J:146561 )

• following treatment with EPO, red cell levels at 6 and 9 days are deficient compared to in similarly treated wild-type mice

increased susceptibility to xenobiotic induced morbidity/mortality ( J:146561 )

• mice treated with a myelosuppressive dose of 5-fluorouracil (5-FU) die between 6 and 16 days post-treatment unlike similarly treated wild-type mice

increased physiological sensitivity to xenobiotic ( J:146561 )

• following treatment with a myelosuppressive dose of 5-fluorouracil (5-FU), mice fail to develop splenomegaly and exhibit reduced erythroblasts and hematocrit levels fall markedly prior to death between 6 and 16 days post-treatment unlike in similarly treated wild-type mice

• following treatment with a standard dose of 5-FU mice exhibit decreased hematocrit levels, red blood cell counts, and delayed recovery compared with similarly treated wild-type mice

• erythrocyte mean cell volume is increased during recovery from a standard dose of 5-fluorouracil (5-FU) compared to in similarly treated wild-type mice

• following treatment with phenylhydrazine (PHZ), mice exhibit decreased erythropoiesis, delayed recovery, deficient hematocrits, decreased spleen cellularity, a 10-fold decrease in splenic erythroblasts, and decreased bone marrow erythroid cells compared with similarly treated wild-type mice

immune system

spleen hypoplasia ( J:146561 )

• following treatment with phenylhydrazine (PHZ)